Mitochondria-Targeting Peptide Elamipretide Rejuvenates Aging Eggs and Restores Fertility in Mice

A single week of treatment with an experimental mitochondria-targeting peptide has restored youthful fertility in middle-aged mice, and early results in human eggs suggest the approach may one day help women whose fertility declines sharply after 35. The study, published in Aging Cell, reports that short-term injections of elamipretide—a small synthetic peptide already tested in clinical trials for heart failure—reversed many of the cellular hallmarks of reproductive aging, from defective spindles and scattered mitochondria to failing energy production and oxidative stress. The work offers one of the most mechanistically complete accounts yet of how an anti-aging drug might rescue the aging egg rather than simply slow its decline.

The biological problem the researchers set out to tackle is well known to reproductive medicine. As women age, the quality of their oocytes deteriorates, driving up rates of miscarriage, chromosomal abnormalities, preterm birth and fetal growth restriction, and making women aged 35 to 39 more prone to infertility than any other age group. Oocyte quality hinges on two tightly coordinated processes: nuclear maturation, in which chromosomes separate during the resumption of meiosis, and cytoplasmic maturation, in which the egg stockpiles the messenger RNAs, proteins and substrates that fertilization and early embryonic development will demand. Aging disrupts the cytoplasmic arm of this program through mitochondrial dysfunction, disturbed calcium signaling, malformed smooth endoplasmic reticulum and cytoskeletal disarray.

Mitochondria sit at the center of that failure. The oocyte is one of the most energy-hungry cells in the body, relying on oxidative phosphorylation through the five complexes of the electron transport chain to power chromosome segregation, spindle migration and organelle repositioning. In aging oocytes, the respiratory capacity of each mitochondrion falls and the mitochondrial membrane potential drops, a shift typically accompanied by a surge in reactive oxygen species. That oxidative burst damages nuclear and mitochondrial DNA, destabilizes the meiotic spindle and can ultimately produce aneuploid eggs. Previous metabolic surveys of aging ovaries found depletion of NAD+, purines and pyrimidines alongside an accumulation of glycolysis substrates and glutamine, painting a consistent picture of failing mitochondrial metabolism.

Researchers have tried a succession of interventions to prop up the aging egg: the CD38 inhibitor 78c to raise NAD+ levels, rapamycin to restore protein homeostasis, melatonin to quench oxidative stress, spermidine to enhance mitophagy, and mitochondria-targeted antioxidants such as MitoQ and SkQ1, along with NAD+ boosters like nicotinamide mononucleotide and the electron carrier CoQ10. Each has shown promise, but low targeting efficiency and poor bioavailability have limited clinical translation. Elamipretide, a membrane-penetrating aromatic cationic tetrapeptide with the sequence Arg-Dmt-Lys-Phe-NH2, was attractive to the team precisely because it is small, water-soluble, resistant to peptidase degradation and stable in solution—properties that make it a plausible candidate for real-world clinical use.

The peptide’s mechanism is unusually specific. At physiological pH it carries three positive charges and accumulates in the inner mitochondrial membrane through electrostatic and hydrophobic interactions, where it binds with high affinity to cardiolipin, a signature phospholipid of that membrane. Cardiolipin is central to respiratory chain supercomplex assembly, membrane stability and energy transduction, but it is also vulnerable to oxidation under oxidative stress, which disrupts the membrane, saps electron transport efficiency and diminishes ATP output. By binding cardiolipin, elamipretide inhibits the peroxidase activity of cytochrome c, prevents cardiolipin oxidation and preserves the cristae architecture of the inner membrane, stabilizing energy production and cutting back the generation of reactive oxygen species.

To test whether these properties could rescue the aging ovary, the team treated 10-month-old mice—well past the mouse reproductive prime—with daily intraperitoneal injections at 3, 5 or 10 milligrams per kilogram. The 5 mg/kg dose proved optimal, and a seven-day course was the most effective duration, improving reproductive performance in 8-, 10- and 12-month-old animals with the strongest gains in the 10-month group. Ovarian sections showed a marked increase in high-quality dominant follicles, fertilization rates of aged oocytes rose substantially, and early embryonic development recovered: aged oocytes normally stall between the two-cell and four-cell stages after fertilization, but elamipretide effectively reversed that block. The benefit, however, was transient, lasting only about a month, which the authors note defines both the promise and the limits of the regimen.

Molecular profiling revealed an unexpected metabolic handle on the effect. Metabolomics of treated ovaries showed that elamipretide shifted the aged metabolome back toward a young-like profile, and pathway analysis singled out vitamin B6 metabolism as the most dramatically altered route. When the team supplemented aged oocytes directly, vitamin B6—but not the other strongly altered metabolites, L-acetylcarnitine and aminovaleric acid—fully reversed the age-associated decline in first polar body extrusion, the hallmark of successful nuclear maturation. Transcriptomics then pointed to the vascular endothelial growth factor pathway, whose age-elevated expression was normalized by the peptide. Blocking VEGF-A transcription with the inhibitor PTC299 reproduced many of elamipretide’s benefits in aged oocytes, restoring mitochondrial positioning, damping the ROS surge, repairing spindle defects and correcting chromosome misalignment, while PI3K/AKT inhibitors failed to do so—placing VEGF-A, acting downstream of vitamin B6 metabolism, at the heart of the mechanism.

Under the microscope, the cellular rescue was striking. Aged oocytes typically display aberrant spindles and scattered chromosomes, loss of γ-tubulin foci at the spindle poles, and reduced acetylation of tubulin, a marker of microtubule instability. Elamipretide restored all of these, along with the cytoplasmic actin network that aging disrupts, and it recovered the expression of ROCK1/2, proteins involved in actin assembly. Mitochondria, which drift away from the spindle and clump in the cytoplasm of aged eggs, returned to their proper peri-spindle domain; ATP levels normalized, mitochondrial DNA copy number partially rebounded, membrane potential rose and ROS fell. The peptide also repaired organelle systems beyond the mitochondria: Golgi markers Rab10 and GM130, endoplasmic reticulum positioning and the ER stress marker GRP78, lysosomal distribution and LC3-mediated autophagic flux all returned toward youthful patterns, indicating a coordinated restoration of cytoplasmic maturation.

Crucially, the findings were not confined to mice. In a randomized in vitro experiment approved under the Declaration of Helsinki, germinal vesicle oocytes from 39 patients undergoing intracytoplasmic sperm injection were cultured with or without 500 micromolar elamipretide. Among women aged 35 and older—three patients contributing 54 oocytes—the peptide improved maturation at both 24 and 48 hours and raised fertilization and cleavage rates after ICSI, with similar gains in younger women’s oocytes. In pigs, whose oocytes are a standard translational model, elamipretide at 1 millimolar rescued maturation in eggs subjected to hydrogen-peroxide-induced oxidative stress, restoring mitochondrial distribution, LC3 expression and apoptosis levels. The authors conclude that short-term elamipretide treatment reverses age-related oocyte decline through a vitamin B6–VEGF axis that jointly rescues nuclear and cytoplasmic maturation. Because the peptide has already advanced into human trials for cardiac and neuromuscular indications, the path from mouse ovary to fertility clinic may be shorter than for most laboratory discoveries—though the transient one-month window of benefit and the small human sample mean considerable work remains before any clinical application.

Subject of Research: Mitochondria-targeted peptide therapy for age-related decline in oocyte quality and female fertility

Article Title: Elamipretide Rejuvenates Oocyte Quality and Restores Female Fertility During Reproductive Aging

Article References: Zhang, H.-L., Wang, Y., Wang, C., Guo, X., Chen, H., Hou, Y.-X., Wu, X., Wu, Z.-J., Pan, W.-L., Ma, R.-J., Lu, P.-S., Shu, J., & Sun, S.-C. (2026). Elamipretide Rejuvenates Oocyte Quality and Restores Female Fertility During Reproductive Aging. Aging Cell, 25(10), Article e70749. https://doi.org/10.1111/acel.70749

Image Credits: AI Generated

DOI: 10.1111/acel.70749

Keywords: elamipretide, oocyte aging, female fertility, mitochondria, cardiolipin, vitamin B6, VEGF, oxidative stress, meiotic spindle, reproductive aging, in vitro maturation, Aging Cell